Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hepatitis C virus NS3-NS4A serine protease is a membrane-associated, non-covalent heterodimeric complex essential for HCV replication. It functions to cleave the viral polyprotein at multiple sites, releasing mature viral proteins. Its role in both viral replication and immune evasion makes it a prime target for antiviral drug development. Approved drugs like boceprevir, telaprevir, and paritaprevir specifically inhibit its proteolytic function, leading to significant improvements in treatment outcomes for chronic hepatitis C patients.
Inhibition of viral protease activity, preventing polyprotein processing and viral replication.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis C virus NS3-NS4A serine protease (NS3/4A protease).